Literature DB >> 15936901

Induction of macrolide resistance in Mycoplasma gallisepticum in vitro and its resistance-related mutations within domain V of 23S rRNA.

Cong-Ming Wu1, Huiming Wu, Yibao Ning, Jianguo Wang, Xiangdang Du, Jianzhong Shen.   

Abstract

Antibiotic-resistant mutants of Mycoplasma gallisepticum were selected in vitro from the susceptible strains S6 and BG44T by serial passages in stepwise concentrations of erythromycin, tylosin, or tilmicosin. High resistance to erythromycin or tilmicosin developed readily, whereas resistance to tylosin developed only after greater numbers of passages. Three mutants selected by each selector antibiotic were cloned and detected, and all cloned mutants exhibited cross-resistance to the three selector antibiotics as well as to lincomycin. Portions of the genes encoding domain V of 23S rRNA of the cloned mutants were amplified by PCR, and their nucleotide sequences were compared to those of the susceptible parent strains. Five of the six mutants selected by erythromycin harbored an A2058G (Escherichia coli numbering) mutation in one of the two 23S rRNA. One of the six mutants selected by erythromycin harbored a G2057A mutation and an A2059G mutation in the other 23S rRNA. In tilmicosin-selected mutants, two mutations, A2058G and A2503U, occurred in one of the two 23S rRNA. No mutation was detected in the two 23S rRNA of tylosin-selected mutants with low-level resistance. Mutations at homologous locations in the 23S rRNA of other macrolide-resistant bacteria indicate that the phenotype of macrolide resistance occurring in M. gallisepticum is strongly associated with point mutations in domain V of 23S rRNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936901     DOI: 10.1016/j.femsle.2005.05.012

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  7 in total

1.  Characterization of in vivo-acquired resistance to macrolides of Mycoplasma gallisepticum strains isolated from poultry.

Authors:  Irena Gerchman; Sharon Levisohn; Inna Mikula; Lucía Manso-Silván; Inna Lysnyansky
Journal:  Vet Res       Date:  2011-08-02       Impact factor: 3.683

2.  Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Lilla Fekete; Veronika Hrivnák; Tibor Magyar; Szilárd Jánosi; Nóra Schweitzer; Ibolya Turcsányi; László Makrai; Károly Erdélyi; Miklós Gyuranecz
Journal:  BMC Vet Res       Date:  2014-10-25       Impact factor: 2.741

3.  Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and Valnemulin.

Authors:  Nan Zhang; Xiaomei Ye; Yuzhi Wu; Zilong Huang; Xiaoyan Gu; Qinren Cai; Xiangguang Shen; Hongxia Jiang; Huanzhong Ding
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

4.  Antibiotic susceptibility profiles of Mycoplasma synoviae strains originating from Central and Eastern Europe.

Authors:  Zsuzsa Kreizinger; Dénes Grózner; Kinga M Sulyok; Kristin Nilsson; Veronika Hrivnák; Dušan Benčina; Miklós Gyuranecz
Journal:  BMC Vet Res       Date:  2017-11-17       Impact factor: 2.741

5.  Emergence and Mechanism of Resistance of Tulathromycin Against Mycoplasma hyopneumoniae in a PK/PD Model and the Fitness Costs of 23S rRNA Mutants.

Authors:  Xirui Xia; Lan Yang; Yuzhou Ling; Jiao Yu; Huanzhong Ding
Journal:  Front Vet Sci       Date:  2022-02-11

6.  Proteomic analysis of tylosin-resistant Mycoplasma gallisepticum reveals enzymatic activities associated with resistance.

Authors:  Xi Xia; Congming Wu; Yaowen Cui; Mengjiao Kang; Xiaowei Li; Shuangyang Ding; Jianzhong Shen
Journal:  Sci Rep       Date:  2015-11-20       Impact factor: 4.379

7.  Antibiotic susceptibility profiles of Mycoplasma sp. 1220 strains isolated from geese in Hungary.

Authors:  Dénes Grózner; Zsuzsa Kreizinger; Kinga M Sulyok; Zsuzsanna Rónai; Veronika Hrivnák; Ibolya Turcsányi; Szilárd Jánosi; Miklós Gyuranecz
Journal:  BMC Vet Res       Date:  2016-08-19       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.